Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors

Molecular Medicine

Volumn 15, Issue 5-6, 2009, Pages 183-191

  Argyriou, Andreas A ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IPILIMUMAB; IRINOTECAN; MATUZUMAB; MDX 101; MDX 447; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; NIMOTUZUMAB; OREGOVOMAB; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PLACEBO; PLATINUM; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; KIDNEY CANCER; LEUKOPENIA; LOADING DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RECURRENT CANCER; REVIEW; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GENES, ERBB-2; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66449117957     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00007     Document Type: Review

References (66)

1. Lambert JM. (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol.5:543-9.
2. Vulfovich M Saba N. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opin. Investig. Drugs13:577-607.
3. Rosa DD, Ismael G, Lago LD, Awada A. (2008) Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat. Rev.34:61-80.
4. Dalle S, Thieblemont C, Thomas L, Dumontet C (2008) Monoclonal antibodies in clinical oncology. Anticancer Agents Med. Chem.8:523-32.
5. Yan L, Hsu K, Beckman RA (2008) Antibody-based therapy for solid tumors. Cancer J.14:178-83.
6. Green MC, Murray JL, Hortobagyi GN. (2000) Monoclonal antibody therapy for solid tumors. Cancer Treat. Rev.26:269-86.
7. Laskin JJ, Sandler AB. (2004) Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev.30:1-17.
8. Lenz HJ. (2006) Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 20(5 Suppl 2):5-13.
9. Kalofonos HP, Grivas PD. (2006) Monoclonal antibodies in the management of solid tumors. Curr. Top. Med. Chem.6:1687-705.
10. Vogel CL, et al.(2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20:719-26.
11. Baselga J, et al.(2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol.23:2162-71.
12. Burstein HJ, Keshaviah A, Baron AD, et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer110:965- 72.
13. Sato N, et al.(2006) Combination docetaxel and trastuzumab treatment for patients with HER-2- overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer13:166-71.
14. Schaller G, et al.(2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthra-cyclines or taxanes. J. Clin. Oncol.25:3246-50.
15. Hussain MH, et al.(2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol.25:2218-24.
16. Viani GA, et al.(2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer7:153.
17. Suter TM, et al.(2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J. Clin. Oncol.25:3859-65.
18. Belkacémi Y, et al.(2008) Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann. Oncol.19:1110-6.
19. Arnould L, et al.(2007) Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin. Cancer Res.13:6404-9.
20. Coudert BP, et al.(2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J. Clin. Oncol.25:2678-84.
21. Gianni L, et al.(2007) Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): anti- tumour and safety analysis [abstract]. J. Clin. Oncol.25:532.
22. Balin-Gauthier D, et al.(2006) In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother. Pharmacol.57:709-18.
23. Prichard CN, et al.(2007) Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope117:674-9.
24. Kim S, et al.(2006) Cetuximab and irinotecan interact synergistically to inhibit the growth of or-thotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res.12:600-7.
25. Thienelt CD, et al.(2005) Multicenter phase I/II study of cetuximab with paclitaxel and carbo-platin in untreated patients with stage IV non- small-cell lung cancer. J. Clin. Oncol.23:8786-93.
26. Modi S, et al.(2006) A phase I study of cetuximab/ paclitaxel in patients with advanced-stage breast cancer. Clin. Breast Cancer7:270-7.
27. Belani CP, et al.(2008) Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage non small cell lung cancer: a multicenter phase 2 study. Cancer113(9):2512-7.
28. Hofheinz RD, et al.(2006) Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neo- adjuvant therapy for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.66:1384-90.
29. Jonker DJ, et al.(2007) Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.357(20):2040-8.
30. Tabernero J, et al.(2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metasta- tic colorectal cancer. J. Clin. Oncol.25(33):5225- 32.
31. Bourhis J, et al.(2006) Phase I/II study of cetuximab in combination with cisplatin or carbo-platin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.24:2866-72.
32. Lenz HJ, et al.(2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol.24:4914-21.
33. Saltz LB, et al.(2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol.25:4557-61.
34. Burtness B, et al.(2005) Phase III randomized trial of cisplatin plus placebo compared with cis- platin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol.23:8646-54.
35. Curran D, et ai.(2007) Quality of life in head and neck cancer patients after treatment with highdose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol.25:2191-7.
36. Karapetis CS, et al.(2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359:1757-65.
37. Di Nicolantonio F, et al.(2008) Wild-type BRAF is required for response to panitumumab or cetux- imab in metastatic colorectal cancer. J. Clin. Oncol.26:5705-12.
38. Fuchs CS, et al.(2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol.25:4779-86.
39. Giantonio BJ, et al.(2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colo- rectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25:1539-44.
40. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O (2009) Addition of bevacizumab to fluorouracil- based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J. Clin. Oncol.27:199-205.
41. Grothey A, et al.(2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol.26:5326-34.
42. Miller KD, et al.(2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23:792-9.
43. Ramaswamy B, et al.(2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res.12:3124-9.
44. Sandler A, et al.(2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355:2542-50.
45. Herbst RS, et al.(2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol.25:4743-50.
46. Bukowski RM, et al.(2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol.25:4536-41.
47. Rini BI, et al.(2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26:5422-8.
48. Kindler HL, et al.(2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol.23:8033-40.
49. Rini BI, et al.(2006) Combination immunotherapy with prostatic acid phosphatase pulsed antigen- presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer107:67-74.
50. Varker KA, et al.(2007) A randomized phase 2 trial of bevacizumab with or without daily low- dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol.14:2367-76.
51. Van Cutsem E, et al.(2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25:1658-64.
52. Hecht JR, et al.(2007) Panitumumab monother- apy in patients with previously treated metasta- tic colorectal cancer. Cancer110:980-8.
53. Hecht JR, et al.(2008) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27:672-80.
54. Graeven U, et al.(2006) Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemc- itabine in advanced pancreatic cancer. Br. J. Cancer94:1293-9.
55. Kollmannsberger C, et al.(2006) A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol.17:1007-13.
56. Seiden MV, et al.(2007) A phase II trial of EMD72000 (matuzumab), a humanized anti- EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol.104:727-31.
57. Crombet T, et al.(2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol.22:1646-54.
58. Fury MG, et al.(2008) A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol. Immunother.57:155-63.
59. Ehlen TG, et al.(2005) A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer15:1023-34.
60. Berek JS, et al.(2004) Randomized, placebo- controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol.22:3507-16.
61. Berek JS, Taylor PT, Nicodemus CF. (2008) CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab im- munotherapy in advanced ovarian cancer. J. Im- munother.31:207-14.
62. Herbst RS, et al.(2007) Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin. Cancer Res.13:6175-81.
63. Gordon MS, et al.(2006) Clinical activity of per- tuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol.24:4324-32.
64. Agus DB, et al.(2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J. Clin. Oncol.25:675-81.
65. Weber J. (2007) Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune- related adverse events. Oncologist12:864-72.
66. Weber JS, et al(2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol.26:5950-6.